Levetiracetam

pharmacological · nervous · Oral · IV

Levetiracetam. Pyrrolidone antiseizure — binds synaptic vesicle protein 2A (SV2A) reducing synaptic neurotransmitter release. Broad-spectrum +… Oral half-life 7.3 h.

Pyrrolidone antiseizure — binds synaptic vesicle protein 2A (SV2A) reducing synaptic neurotransmitter release. Broad-spectrum + best-tolerated newer antiseizure agent. Renally cleared, no CYP — DDI-light. Behavioral side effects (irritability, depression) in some patients.

PK: the oral half-life 7.3 h is verbatim and stands (PMID:17324224, 26 healthy men). The IV row was filed under that ORAL-ONLY study and now cites Ramael 2006 (PMID:16886975), verbatim "terminal half-life, 8.0 (14.5%) and 7.0 (12.7%) h" for two IV infusion arms. V 42 L was the midpoint of a review 0.5-0.7 L/kg x 70 kg; replaced by 35.1 L from a population fit (PMID:39932425) and F pinned to 1 because that is an apparent V/F. Oral and IV are bioequivalent, "geometric mean IV/oral ratios were 92.2 ... for AUC" (PMID:16861095). ka 4 /h dropped: unstated, and it predicts a Tmax near 1 h against the cited paper own median of 0.5 h.

Pharmacokinetics

• Oral — t½ 7.3 h · F 100% · Vd 35.1 L
• IV — t½ 8 h · F 100%

Sources: PMID:15301575, PMID:39932425, PMID:16861095, PMID:16886975